期刊文献+

维拉帕米对心肌细胞的保护与毒性作用 被引量:2

The protection and cytotoxity of verapamil on heart cells
下载PDF
导出
摘要 目的研究维拉帕米(verapamil,Ver)对心肌细胞的保护作用与毒性。方法体外培养心肌细胞,测定培养液中乳酸脱氢酶(LDH)、肌酸磷酸激酶(CK)的活性;观察不同浓度维拉帕米对心肌细胞的毒性作用及对缺氧再复氧模拟"缺血再灌注"细胞的保护作用。结果连续培养96 h的结果与正常对照组相比,Ver 10.0 mg/L以上各浓度组存活细胞代谢比色值A540减少、LDH活性增高具有明显的意义;比色值A540与细胞释放的LDH、CK活性呈高度相关(r=-0.986、-0.989,P<0.01);维拉帕米可使缺血再灌注损伤的心肌细胞A540显著升高、CK显著降低。结论维拉帕米在缺氧再复氧时有明显的细胞保护作用,但是高浓度特别是超过10 mg/L时的直接细胞毒性作用值得关注。 Objective To study the protection and cytotoxity of verapamile on heart cells. Methods Heart cells were cuhured. The activity of lactate dehydrogenase and creatine phosphokinase in culture medium was detected. The toxicity of verapamil to heart cells in different concerntra/ion and protective role of verapamil to heart cells during hypoxia-reoxygennation were observed by MTT assay and testing of CK and LDH activity. Results By continuously incubation for 96 h, the value of A540 decreased and LDH activity increased in cultured heart cells with the concentration of verapamil at 10.0 mg/L or higher compared with control cells. A540 response curves were highly correlated with CK activity ( r = -0. 986, P 〈0.01 ) and LDH activity ( r = -0. 989, P 〈0.01 ). The value of A540 significantly increase and CK activity obviously reduce in heart cells simulative ischemia and reperfusion after treatment with verapamil. Conclusion Verapamil protects heart cells in simulative ischemia and reperfusion, but the cytotoxicity is worth paying close attention when verapamil concentration is over 10 mg/L.
机构地区 解放军
出处 《东南国防医药》 2010年第1期21-23,共3页 Military Medical Journal of Southeast China
关键词 心肌细胞 维拉帕米 保护 细胞毒性 乳酸脱氢酶 肌酸磷酸激酶 heart cell verapamil protection cytotoxity lactic dehydrogenase(LDH) creatine kinase (CK)
  • 相关文献

参考文献9

二级参考文献16

  • 1何奔,丁嵩,卜军,刘建平,宋玮,杜勇平,沈节艳,金叔宣,孙瑜,沈珑.脑利钠肽和C-反应蛋白在急性冠状动脉综合征介入治疗患者的预后价值[J].中华心血管病杂志,2006,34(4):349-352. 被引量:56
  • 2Assail AR.Sdringola S,Ghani M,et al.Intracoronary adenosine admininstered during pereutaneous intervention in acute myocardial infarction and reduction in the incidence of "no rcflow" phenomenon.Catheter Cardiovasc Interv,2000,51:27-31.
  • 3Gibson CM,Cannon CP.Murphy SA,et al.for the TIMI study group.Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drags.Circulation,2000,101:125-130.
  • 4Poao I,Ashar V,Mitchell ARJ,et al.Pharmacolngical Management of No Reflow During Percutaneous Coronary Intervention.urrent Vaacutar Pharmacology,2006,4:95-100.
  • 5Vijayatakshmi K,Ashton V,Wright R,et al.Corrected TIMI frame count(cTFC):applicability in modem digital catheter laboratories when different frame acquisition rates are used.Catheter Cardiovasc Interv,2004,63:426-432.
  • 6The TIMI Study Group.The Thrombolysis in Myocardial Infarction (TIMI) trial.N Engl J Med,1985,312:932-936.
  • 7Gibson CM,Cannon CP,Daley WL,et al.TIMI frame count:a quantitative method of assessing coronary artery flow.Circulation,1996.93:879-888.
  • 8Gibson,CM,Murphy,SA,Rizzo,MJ,et al.Relationship between TIMI frame count and clinical outcomes after thrombolytic administration.Thmmbolysis In Myocardial Infarction.(TIMI) Study Group.Circulation,1999,99:1945-1950.
  • 9van't Hof AWJ,Liem A,Suryapranata H,et al.Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myacardial infarction:myocardial blush grade:Zwolle Myocardial Infarction Study Group.Circulation,1998,97:2302-2306.
  • 10Nagata Y,Usuda K,Uchiyama A,et al.Characteristics of the pathological images of coronary artery thormbi according to the infarct-related coronary artery in acute myocardial infarction.Circ J,2004,68:308-314.

共引文献17

同被引文献21

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部